These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 19875949)

  • 1. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
    Matsuo K; Eno ML; Im DD; Rosenshein NB
    Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
    Leiser AL; Chi DS; Ishill NM; Tew WP
    Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer.
    Pant AC; Diaz-Montes T; Tanner E; Ahmad S; Giuntoli RL; Holloway RW; Bristow RE
    J Chemother; 2010 Aug; 22(4):270-4. PubMed ID: 20685633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
    Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
    Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinosarcoma of the ovary-a case series.
    Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS
    Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience.
    Chun KC; Kim JJ; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Gynecol Obstet Invest; 2011; 72(3):208-14. PubMed ID: 21968161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study.
    Kim HS; Kim TJ; Chung HH; Kim JW; Kim BG; Park NH; Song YS; Bae DS; Kang SB
    J Cancer Res Clin Oncol; 2009 Nov; 135(11):1513-20. PubMed ID: 19449027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
    Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
    J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinosarcoma of the ovary: 19 years of prospective data from a single center.
    Brown E; Stewart M; Rye T; Al-Nafussi A; Williams AR; Bradburn M; Smyth J; Gabra H
    Cancer; 2004 May; 100(10):2148-53. PubMed ID: 15139057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW; Orr P; Kern DH
    Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extreme drug resistance is common after prior exposure to paclitaxel.
    Geisler JP; Linnemeier GC; Thomas AJ; Manahan KJ
    Gynecol Oncol; 2007 Sep; 106(3):538-40. PubMed ID: 17561236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature.
    Loizzi V; Cormio G; Camporeale A; Falagario M; De Mitri P; Scardigno D; Putignano G; Selvaggi LE
    Oncology; 2011; 80(1-2):102-6. PubMed ID: 21677454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.